Integrating Public Health Concerns into Patent Legislation in Developing Countries
(2000; 140 pages) [French] [Spanish] Ver el documento en el formato PDF
Índice de contenido
Ver el documentoTHE SOUTH CENTRE
Ver el documentoFOREWORD
Ver el documentoACKNOWLEDGEMENTS
Ver el documentoGLOSSARY*
Abrir esta carpeta y ver su contenidoI. INTRODUCTION
Abrir esta carpeta y ver su contenidoII. PATENTABLE SUBJECT MATTER
Abrir esta carpeta y ver su contenidoIII. SCOPE OF CLAIMS
Abrir esta carpeta y ver su contenidoIV. PATENTABILITY REQUIREMENTS
Cerrar esta carpetaV. SPECIAL CASES IN PHARMACEUTICALS
Ver el documentoV.1 Selection Patents
Ver el documentoV.2 Prior Public Availability
Ver el documentoV.3 Polymorphism
Ver el documentoV.4 Analogy processes
Ver el documentoV.5 Compositions
Ver el documentoV.6 Optical Isomers
Ver el documentoV.7 Active Metabolites
Ver el documentoV.8 Prodrugs
Abrir esta carpeta y ver su contenidoVI. DISCLOSURE
Abrir esta carpeta y ver su contenidoVII. EXCEPTIONS TO EXCLUSIVE RIGHTS
Abrir esta carpeta y ver su contenidoVIII. EXAMINATION AND OBSERVATION PROCEDURES
Abrir esta carpeta y ver su contenidoIX. CLAIMS INTERPRETATION
Abrir esta carpeta y ver su contenidoX. COMPULSORY LICENSING
Ver el documentoXI. FINAL REMARKS
Ver el documentoREFERENCES
Ver el documentoBACK COVER
 

V. SPECIAL CASES IN PHARMACEUTICALS

Several issues relating to the application of patentability requirements may be specific to health-related inventions. WTO Member countries retain a considerable degree of flexibility in addressing most of them. These issues may be appropriately treated in implementing regulations and/or guidelines for the patent office, rather than in the law itself.

Developing countries, particularly those implementing for the first time the patenting of product pharmaceutical inventions, should carefully craft policy in these areas to ensure that patents are granted to real contributions to the prior art and to avoid granting to trivial inventions patents that impede competition. Poor drafting or administration of patent laws may also permit abusive practices that illegitimately extend patent protection beyond the 20-year term.

Ir a la sección anterior
Ir a la siguiente sección
 
 
El Portal de Información - Medicamentos Esenciales y Productos de Salud de la OMS fue diseñado y es mantenido por la ONG Human Info. Última actualización: le 1 diciembre 2019